Profiles in Prognosis for HCM
|
|
- Geraldine McCormick
- 5 years ago
- Views:
Transcription
1 Japan N=3,354;20-77 y 0.17% CARDIA N=4,111; y 0.17% Rural Minnesota N=15,137; y 0.19% Amer Indians N=3,501;51-77 y 0.2% General Population 1:500 China N=8,080; y 0.16% 600,000 people in U.S. AT RISK: 50, ,000? Profiles in Prognosis for HCM Sudden Death Risk Symptom Progression End- Stage AF
2 Arrhythmogenic Myocardial Substrate in HCM Maron BJ et. al. Circulation 2000; 102:858 % HCM Mortality Per Age Group Sudden Stroke Heart Failure >75 Age at Death or Most Recent Evaluation (years)
3 2 prevention Cardiac arrest/sustained VT 1 prevention Familial sudden death Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response Massive LVH Potential arbitrators End-stage phase LV apical aneurysm Marked LV outflow obstruction (rest) Extensive delayed enhancement Modifiable Intense competitive sports CAD Alcohol septal ablation (?) Mutations ± Highest Intermediate Lowest ICD
4 % Patients With SCD Relation Between LV Thickness & SCD in 480 HCM Patients < Max. LV Wall Thickness (mm) Spirito et. al. NEJM 2000; 342: prevention Cardiac arrest/sustained VT 1 prevention Familial sudden death Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response Massive LVH Potential arbitrators End-stage phase LV apical aneurysm Marked LV outflow obstruction (rest) Extensive delayed enhancement Modifiable Intense competitive sports CAD Alcohol septal ablation (?) Mutations ± Highest Intermediate Lowest ICD
5 A P VS D B P Maron MS et. al. Circulation 2008; Figure 118: D C VS P D LA D E F * * * * * * Patients with LVAA (n=28) Maron MS et. al. Circulation 2008; 118:1541 Alive/ Clinically Stable (n = 16)* Adverse Events (n = 12) non-fatal embolic stroke (1) Sudden Death (2)* Aborted Cardiac Arrest (2) Progressive Heart Failure/ Death (5) Appropriate ICD Discharge (3)* non-fatal embolic stroke (1) Cardiovascular Event Rate = 11%/year
6 2 prevention Cardiac arrest/sustained VT 1 prevention Familial sudden death Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response Massive LVH Highest ICD Potential arbitrators End-stage phase LV apical aneurysm Marked LV outflow obstruction (rest) Extensive delayed enhancement Modifiable Intense competitive sports CAD Alcohol septal ablation (?) Mutations ± Intermediate Lowest Septal Scarring Post-ablation Post-myectomy Septal Scar VS=30% LV10% No Scar Valeti et. al. JACC 2007;49:350
7 % Patients With Sustained VT/VF/SD Ventricular Tachyarrhythmias and Sudden Death Following Alcohol Septal Ablation 5% 37/386 = 10% 7% 10% 24% 25% Sorajja Cuoco Noseberry Maron van der Lee 2 prevention Cardiac arrest/sustained VT 1 prevention Familial sudden death Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response Massive LVH Highest ICD Potential arbitrators End-stage phase LV apical aneurysm Marked LV outflow obstruction (rest) Extensive delayed enhancement Modifiable Intense competitive sports CAD Alcohol septal ablation (?) Mutations ± Intermediate Lowest
8 Sudden Death in Young Athletes Other (5%) Possible HCM* ( 8%) HCM (36%) WPW (2%) Dilated CM (2%) AS (3%) Aortic Rupture (3%) CAD (3%) LAD Bridge (3%) MVP (4%) ARVC (4%) Ion Channel (4%) Myocarditis (6%) Coronary Anomalies (17%) Maron, BJ et. al. Circulation 2009; 119: Hypertrophic Cardiomyopathy Sarcomeric Protein Mutations Non-Sarcomeric Mutations ~ 11 Genes--- or more? > 1000 mutations AMP-Kinase (PRKAG2) Lamp2 (Danon) Storage Diseases Fabry Disease
9 Risk Stratification for Sudden Death in HCM Family history of sudden death Extreme LVH Nonsustained VT Unexplained syncope Abnormal BP response to Ex High Intermediate Moderate No risk factors Low Risk Multicenter Study on Sudden Death in Low Risk Patients with HCM Study population = 721 Low Risk patients Total number of sudden deaths = 22 Prevalence = 3% Incidence = 0.5%/yr
10 Foci For Ventricular Arrhythmias? VS LV RV p<0.001 p=0.001 p=0.01 Any DE No DE p=0.06 % of HCM Patients with Arrhythmia 24-hour Holter Arrhythmia and Presence of DE NSVT Couplet PVC SVT Adabag et. al. JACC 2008; 51:1369
11 1.00 Presence of DE vs. Events Event-free rate DE (+) DE (-) N=202 N = 202 Follow-up: avg 2 years p = Follow-up Duration (years) Maron MS et. al. Circ HF 2008; 1:184 DE as the Only Risk Factor A B VS AML LV FW C Maron BJ et. al. AJC 2008; 101:544
12 Family T (as of ) (40s) (85) (45) SCD (100) (73) (77) MyBPC + ctnl + No Risk Factors (39) MyBPC + ctnl + Survived CA 37 y (32) ctnl + (4) MyBPC + ctnl + ctnl MyBPC Arg145Trp Gln998Glu Prevention of Sudden Death In HCM
13 35 y Brother SD (age 39) 36 y ICD 5 y: 9 y: 40 y Generator replaced 41 y Appropriate shock #1 50 y Appropriate shock #2 53y Present HCM is Unpredictable
14 ICD in HCM: Follow-up = 3.7 ± 3 years 103 Appropriate Shocks VT/VF (20%) 5.5%/ yr ICD discharge rate 11% 4% 2º prevention 1º prevention Maron, BJ et. al. JAMA 2007;298:405 Rate of Appropriate Shocks (100 person-yr) % of appropriate shocks Overall p= No. Risk Factors for Primary Prevention Maron, BJ et. al. JAMA 2007;298:405
15 One Risk Factor Patients With Primary Prevention Appropriate Shock Rates/Year Massive LVH Family SD NSVT Syncope (Holter) Maron, BJ et. al. JAMA 2007;298:405 ICD in HCM : Time to First Shock No. Patients >90 Maron, BJ et. al. JAMA 2007;298:405 Duration (months)
16 Primary Prevention Decision Tree: ICD In HCM Risk Factors High-- risk? Some risk Cardiologist TRANSPARENCY / FULL DISCLOSURE / INFORMED CONSENT Patient Autonomy HCM ICD Registry 29 (6%) Deaths 14 No HCM HCM HCM- Arrhythmias (nl EF) 1 Cancer, sepsis, renal diseases, suicide, CAD, accidents 14 End-stage Embolic stroke ICD Malfunction Maron, BJ et. al. JAMA 2007;298:405
17 Risk Stratification and ICD Decision-Making in HCM Current risk factors are a useful guide 1 risk factor can be enough (but not obligatory) for ICD Risk factors cannot be summed numerically; all with low PPV Absence of risk factors does not confer immunity from SD ICD decisions may also be based on: individual physician judgment/patient autonomy Benign/Stable (normal longevity) Profiles in Prognosis for HCM Sudden Death Risk Symptom Progression End Stage AF ICD
18
19 High-Risk Children with HCM and ICDs Implanted < 20 years: Appropriate shocks: Age at intervention: Implanted < 15 years: Appropriate shocks: Age at intervention: (28%;7%/y) years (35%;11%/y) years
20 Bethesda Conference # 36 Recommendations Athletes with the unequivocal diagnosis of hypertrophic cardiomyopathy should not participate in most competitive sports, with the possible exception of those of low intensity. This recommendation includes those athletes with or without symptoms and with or without left ventricular outflow obstruction. A Echo B CMR RV VS * RV VS LV * * LV Maron MS et. al. in press
21 A 73y/F B 77y/M VS * * C 37y/M * * Family T After the Shock?
22 Trading SD for CHF Moss et. al. MADIT-II Circulation 2004; 110: Clinical Status Post Appropriate ICD Shock I NYHA Class: Initial VT/VF NYHA Class: At follow-up % II III Maron, BJ et. al. Heart Rhythm 2009; 6:993
23 A B VS Ao VS MAC C D A LV C VS * * RV VS D B E RV VS * * * * LV
24 Outcome of HCM Patients First Evaluated at 60 Years Old 70 65% 60 % of HCM Cohort Alive 13% Non- Cardiac Death 12% Non-HCM Cardiac Death 2% 1% 1% Embolic Stroke Heart Failure HCM Death 0.2%/y SCD Management of HCM Key Elements Screening of relatives for HCM Risk assessment for prevention SCD Avoid competitive sports, volume depletion, isometric exercise Control exertional symptoms Older, asymptomatic patients Reassurance Surveillance Exclude HTN
25 Meta-Analysis of Presence DE and Adverse Cardiovascular Events Total Events + LGE p-value Maron MS et al Mayo Clinic Combined Foci For Ventricular Arrhythmias? VS LV RV
26 p<0.001 p=0.001 p=0.01 Any DE No DE p=0.06 % of HCM Patients with Arrhythmia 24-hour Holter Arrhythmia and Presence of DE NSVT Couplet PVC SVT Adabag et. al. JACC 2008; 51: Presence of DE vs. Events Event-free rate DE (+) DE (-) N=202 N = 202 Follow-up: avg 2 years p = Follow-up Duration (years) Maron MS et. al. Circ HF 2008; 1:184
27 Survival to Advanced Age in HCM 25 % HCM Patients % 14% 8% 0 70 years 75 years 80 years 90 years 2% Survival Age DE as the Only Risk Factor A B VS AML LV FW C Maron BJ et. al. AJC 2008; 101:544
28 Watkins et.al. NEJM 1992; 326: Seidman Lab
29 Relation Between LV Wall Thickness and Sudden Death in 480 HCM Patients Incidence of Sudden Death per 1000 person - years P= < > 30 Maximal LV Wall Thickness (mm) Spirito et. al. NEJM 2000; 342:1778 but how low is Low Risk?
30 Bethesda Conference # 36 Classification Sports (#8) Consensus Panels #2 #3 #4 #5 #6 #7 Congenital Valvular #1 #9 #10 #11 #12 Screening / Dx HCM Other C-M MVP Myocarditis Drugs HTN AED CAD Commotio Arrhythmias Legal Preservation of Life Inappropriate Shocks Lead Complications (25%;5%/y) Infection Thrombosis Recalls
31 Preservation of Life Inappropriate Shocks Lead Complications (25%;5%/y) Infection Thrombosis Recalls Joshua s Implantable Defibrillator Prizm 2 DR Model 1861 (10/4/01) Connector + Backfill tube Short circuit - DF Feedthrough wire Polyimide tubing *Guidant aware 2002 *Did not inform physicians or patients Electronics Battery *Manufacturing changes 1- April November 2002 *Continued to sell units without the changes during 2002 Hermetic Housing
32 ICD in HCM : Age at Implant No. of Patients < >76 Age At Implant (years) Maron, BJ et. al. JAMA 2007;298:405 Circadian Variability for Appropriate ICD Shocks No. of Events Midnight Noon Hour of Day Maron, BJ et. al. Heart Rhythm 2009;6:599
33 Relation between LV Wall Thickness and Sudden Death in 480 Patients Incidence of Sudden Death per 1000 person - years P= < > 30 Maximal LV Wall Thickness (mm) Spirito et al. NEJM 2000 ICD : HCM vs. CAD CAD HCM Implant age ~65 ~40 Risk period short long Substrate often usually compromised intact Intervention / yr ~30% 5%
34 2 prevention Cardiac arrest/sustained VT 1 prevention Familial sudden death Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response Massive LVH Highest ICD Potential arbitrators End-stage phase LV apical aneurysm Marked LV outflow obstruction (rest) Extensive delayed enhancement Modifiable Intense competitive sports CAD Alcohol septal ablation (?) Intermediate Lowest Defibrillator Implants Throughout The World (per million population) United States Germany Canada Ireland Denmark Australia Italy Austria Netherlands Belgium Switzerland Norway Finland United Kingdom Sweden France New Zealand Spain Portugal Japan
35 ICD in HCM No. Patients: 506 Centers: 42 Sites: U.S.; Italy / W.Europe;Australia Age: 42±17 years Gender: 64% male LV outflow obstruction::26% Follow-up::3.7±2.8 years Max. LV thickness: 23± 7mm Previously Proposed Pharmacological Therapy For Sudden Death Prevention in HCM ß-adrenergic blockers verapamil procainamide quinidine amiodarone no data proarrhythmia (obsolete) efficacy? chronic use (>3y)?
36 Impact of Outflow Obstruction (> 30mmHg) on Progression to Severe Heart Failure Related Symptoms and Death in 1101 HCM Patients 100 Cumulative survival in NYHA Class I II (%) p= RR= 4.4 Nonobstructive Obstructive Years from First Gradient Measurement Maron, MS et. al. NEJM 2003;348:295 Principles Patients have a fundamental right to be fully informed when they are exposed to the risk of death no matter how low that risk may be perceived. Patients---and their physicians---are entitled to full disclosure of product information that may affect an individual s health or safety.
37 Profiles in Prognosis for HCM Sudden Death Risk Symptom Progression End- Stage AF ICD Sudden Death in Young Athletes Other congenital HD Ion channelopathies Aortic rupture (2%) Sarcoidosis (1%) Dilated C-M (2%) AS (3%) Other (3%) Normal heart (3%) CAD (3%) Tunneled LAD (3%) HCM (36%) MVP (4%) ARVC (4%) Myocarditis (6%) Coronary artery anomalies (17%) Indeterminate LVH - possible HCM (8%)
38 Septal Myectomy vs. Alcohol Septal Ablation: Appropriate ICD Shocks No. Pts No. Appropriate Shocks % %/Year Surgical myectomy Alcohol septal ablation x p p<0.01 Distribution of Disease - Causing Mutations in HCM Cohort MYBPC3 16% No Mutation 62% MYH7 14% MYL2 2% TNNT2 1.5% TNNI3 1% from Van Driest and Ackerman (Mayo); 2004 Multiple mutations 3% TMP 0.5% ACTC 0.3%
39 Uncommon Diseases 2500 No. Affected / Million HCM Cystic Fibrosis Multiple Sclerosis Muscular Dystrophy LQTS Marfan ALS Brugada Ataxia Primary Prevention of Sudden Death in HCM Over-treatment vs. under-treatment Imperfect risk stratification Patient autonomy Perceived liability ICD is more powerful than our present ability to precisely identify all high risk patients
40 Deaths with ICDs N = 29 (6%) No HCM: 14 Cancer / Sepsis Renal Suicide Accidents CAD HCM: 14 End-stage Embolic stroke HCM Arrhythmia: 1 (ICD malfunction) Clinical Recognition of HCM Acute Event (11%) Sports/Other Screening (4%) w Routine Exam (33%) Symptom Onset (43%) Adabag et.al. AJC 2006;98:1507 Ada Family Screening (13%)
41 Unpredictability Joshua s Implantable Defibrillator Prizm 2 DR Model 1861 (10/4/01) Connector + Backfill tube Short circuit - DF Feedthrough wire Polyimide tubing *Guidant aware 2002 *Did not inform physicians or patients Electronics Battery *Manufacturing changes 1- April November 2002 *Continued to sell units without the changes during 2002 Hermetic Housing
42 Obstacles From Industry II Sprint Quattro Secure model Percent Lead Survival P=0.005 Sprint Fidelis model Implant Months After the Shock?
43 Clinical Status Post Appropriate ICD Shock I NYHA Class: Initial VT/VF NYHA Class: At follow-up % II III Maron, BJ et. al. Heart Rhythm 2009; 6:993 Sudden Death in Young Athletes Other (5%) HC (36%) WPW (2%) Possible HCM* ( 8%) Dilated CM (2%) AS (3%) Aortic Rupture (3%) CAD (3%) LAD Bridge (3%) MVP (4%) ARVC (4%) Ion Channel (4%) Myocarditis (6%) Coronary Anomalies (17%) Maron, BJ et. al. Circulation 2009; 119:
44 One Risk Factor One Risk Factor Patients With Primary Prevention Appropriate Shock Rates/Year Massive LVH Family SD NSVT (Holter) Syncope
Barry J. Maron, MD Hypertrophic Cardiomyopathy Institute Tufts Medical Center Boston, MA. Disclosures: Medtronic (Grantee) GeneDx (Consultant)
How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality Shaped by 50 Years of Clinical Research and Practice Barry J. Maron, MD Hypertrophic Cardiomyopathy Institute
More informationHCM: The Tip Of The Iceberg. HCM Is A Global Disease. Unidentified. 50 countries.all continents. Rural Minnesota N=15,137;16-87 y 0.
HCM Is A Global Disease 5 countries.all continents CARDIA N=4,111;23-35 y.17% Rural Minnesota N=15,137;16-87 y.19% Japan N=3,354;2-77 y.17% Amer Indians N=3,51;51-77 y.2% General Population 1:5 6, people
More informationSudden cardiac death: Primary and secondary prevention
Sudden cardiac death: Primary and secondary prevention By Kai Chi Chan Penultimate Year Medical Student St George s University of London at UNic Sheba Medical Centre Definition Sudden cardiac arrest (SCA)
More informationThe Management of Hypertrophic Cardiomyopathy
The Management of Hypertrophic Cardiomyopathy Evidence and Uncertainties Banff 2013 3058464-0 Management of HCM Key Elements Screen 1 relatives for HCM Serial Echo Genetic testing Assess risk for and prevent
More informationCardiomyopathies. Andre Keren, MD
Cardiomyopathies Andre Keren, MD Cardiomyopathies Heart muscle disease of unknown etiology Elliott P et al. Eur Heart J 2008;29:270-276 Definition of Cardiomyopathies Elliott P et al. Eur Heart J 2008;29:270-276
More informationHYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW?
HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW? Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens LANCET 2013 ESC HCM
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationRisk Factors for Sudden cardiac Death
Risk Factors for Sudden cardiac Death A. Arenal Arrhythmias in competitive sports Disclosure Conflict of interest Advisory board: Medtronic, Boston Scientific Research grants: Medtronic, Boston Scientific,
More informationSudden Cardiac Death in Sports: Causes and Current Screening Recommendations
Sports Cardiology Sudden Cardiac Death in Sports: Causes and Current Screening Recommendations Domenico Corrado, MD, PhD Inherited Arrhytmogenic Cardiomyopathy Unit Department of Cardiac, Thoracic and
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationCardiomyopathy in Fabry s disease
Cardiomyopathy in Fabry s disease Herzinsuffizienzlunch Basel, 11.09.2018 Christiane Gruner Kardiologie, UniversitätsSpital Zürich Content Background / epidemiology Differential diagnosis Clinical presentations
More informationHypertrophic Cardiomyopathy: basics and management
Hypertrophic Cardiomyopathy: basics and management Bette Kim, MD Program Director, Cardiomyopathy Program Director, Roosevelt Hospital Echocardiography Lab Assistant Professor of Clinical Medicine Mount
More informationI have nothing to disclose. Research support from: Cardiac Risk in The Young
I have nothing to disclose. Research support from: Cardiac Risk in The Young Pre-participation screening of Young Athletes: Current Perspective Professor Sanjay Sharma Disclosures: None SCD in Young Athletes
More informationEVALUATION OF THE ATHLETE. Karen Stout, MD Professor, Medicine and Pediatrics University of Washington
EVALUATION OF THE 12 ATHLETE Karen Stout, MD Professor, Medicine and Pediatrics University of Washington NO DISCLOSURES OUTLINE Why evaluate athletes? What s the problem? What evaluation should be done?
More informationThe time you won your town the race We chaired you through the market-place; Man and boy stood cheering by, And home we brought you shoulder high.
The time you won your town the race We chaired you through the market-place; Man and boy stood cheering by, And home we brought you shoulder high. To-day the road all runners come, Shoulder-high we bring
More informationSteel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015
Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant
More informationWhat s new in Hypertrophic Cardiomyopathy?
What s new in Hypertrophic Cardiomyopathy? Dr Andris Ellims HCM Clinic @ The Alfred Hypertrophic Cardiomyopathy = otherwise unexplained LV hypertrophy* 1 in 500 prevalence most common inherited cardiovascular
More informationSudden Cardiac Death and Asians Disclosures
Sudden Cardiac Death and Asians Disclosures 7 February 2009 Asian Heart and Vascular Symposium None Zian H. Tseng, M.D., M.A.S. Assistant Professor of Medicine Cardiac Electrophysiology Section University
More informationHypertrophic Cardiomyopathy: beyond gradient and wall thickness
Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Michael H. Picard, M.D. Massachusetts General Hospital Harvard Medical School no disclosures special thanks to A. Baggish 1 Hypertrophic
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationCardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center
Cardiac Issues in the Adolescent Athlete Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Sudden Cardiac Death Incidence is.6-6.2 % per 100,000 children in the US 20-25 % of the deaths occur
More informationLa valutazione dell atleta: è una strategia salva-vita e costo-efficace?
La valutazione dell atleta: è una strategia salva-vita e costo-efficace? Primo trattato di Medicina Wilson and Jungner s criteria In the 1960s the World Health Organization adopted the Wilson and Jungner
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationEcho Evaluation of the Heart of an Athlete
Echo Evaluation of the Heart of an Athlete 18 th SA Heart Congress, 2017 Johannesburg, South Africa November 9-12, 2017 Naser Ammash. MD Professor of Medicine Practice Chair, Cardiovascular Department
More informationPreventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete
Preventing Sudden Death in Young Athletes Ronn E. Tanel, MD Director, Pediatric Arrhythmia Service UCSF Children s Hospital Associate Professor of Pediatrics UCSF School of Medicine Outline Sudden death
More informationCONGENITAL CORONARY ARTERY ANOMALIES
How to prevent sudden coronary death in the young CONGENITAL CORONARY ARTERY ANOMALIES Cristina Basso, MD, FESC University of Padua, Italy ESC Congress Paris August 29, 2011 DECLARATION OF CONFLICT OF
More informationHYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy
HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure Paolo Spirito, Genoa, Italy Clinical Substrates for Heart Failure Symptoms in HCM Diastolic dysfunction Atrial fibrillation LV outflow obstruction Evolution
More informationPrevention of Sudden Death in ARVC
ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück
More informationSlide 1. Slide 2. Slide 3. Sudden Cardiac Death In Athletes. Epidemiology. Epidemiology. Shaun McMurtry, MD Primary Care Sports Medicine
Slide 1 Sudden Cardiac Death In Athletes Shaun McMurtry, MD Primary Care Sports Medicine Slide 2 Epidemiology College and Professional Athletes 500,000 participants each year Competitive Athletics Estimated
More informationHypertrophic Cardiomyopathy: Patient Management in 2018
Hypertrophic Cardiomyopathy: Patient Management in 2018 Mackram F. Eleid, MD Giornate Cardiologeche Torinesi October 26, 2018 2018 MFMER slide-1 Disclosures No relevant financial relationships to disclose
More informationCardiac hypertrophy : differentiating disease from athlete
Cardiac hypertrophy : differentiating disease from athlete Ario Soeryo Kuncoro, MD, Cardiologist Echocardiography Division, National Cardiovascular Centre Harapan Kita-Jakarta Departement of Cardiology
More informationPre-Participation Athletic Cardiac Screening
Pre-Participation Athletic Cardiac Screening Kimberly A Krabill, MD Pediatric and Fetal Cardiologist Northwest Congenital Heart Care, Division of MedNax Cardiology Update for Primary Care Symposium July
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationArrhythmias (II) Ventricular Arrhythmias. Disclosures
Arrhythmias (II) Ventricular Arrhythmias Amy Leigh Miller, MD, PhD Cardiovascular Electrophysiology, Brigham & Women s Hospital Disclosures None Rhythms and Mortality Implantable loop recorder post-mi
More informationName of Presenter: Marwan Refaat, MD
NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010 I have no actual or potential conflict of interest in relation
More informationSudden Death in Athletes: What is the role of ECG Screening?
Sudden Death in Athletes: What is the role of ECG Screening? Byron K. Lee MD Professor of Medicine Director of EP Laboratory leeb@medicine.ucsf.edu Division of Cardiology Cardiac Electrophysiology Arrhythmias,
More informationCardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death
Cardiac Conditions in Sport & Exercise Dr Anita Green Cardiac Conditions in Sport Sudden Cardiac Death USA - Sudden Cardiac Death (SCD)
More informationHeart Rhythm Disorders. How do you quantify risk?
Heart Rhythm Disorders How do you quantify risk? Heart Rhythm Disorders Scale of the Problem 1/2 population will have an episode of transient loss of consciousness (T-LOC) at some stage in their life.
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Predisposition to Inherited Hypertrophic File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_predisposition_to_inherited_hypertrophic_cardiomyopathy
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationGenetic Cardiomyopathies
2017 HFCT Annual Scientific Meeting The Heart Failure Crosstalk Genetic Cardiomyopathies Teerapat Yingchoncharoen M.D. Ramathibodi Hospital Cardiomyopathy Group of diseases of the myocardium associated
More informationCardiac Resynchronization Therapy. Michelle Khoo, MD
Cardiac Resynchronization Therapy Michelle Khoo, MD 10.7.08 HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations SD in Competitive Athletes
More informationHCM GUIDELINES ESC 2014 HYPERTROPHIC CARDIOMYOPATHY ASYMPTOMATIC PATIENT
HCM GUIDELINES ESC 2014 HYPERTROPHIC CARDIOMYOPATHY ASYMPTOMATIC PATIENT Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens ASYMPTOMATIC
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationSudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification
Sudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification 84th Annual Scientific Meeting of the Aerospace Medical Association May 12-16, 2013 Sheraton Chicago Hotel & Towers,
More informationCases in Stress Echo DISCLOSURE
Cases in Stress Echo Susan Wilansky, MD, FRCP(C), FACC, FASE Mayo Clinic, AZ DISCLOSURE Relevant Financial Relationship(s) None Off Label Usage None 1 Exercise Testing in Patients with HCM (Class IIa)
More informationHypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy From Genetics to ECHO Alexandra A Frogoudaki Second Cardiology Department ATTIKON University Hospital Athens University Athens, Greece EUROECHO 2010, Copenhagen, 11/12/2010
More informationSports Cardiology: Matters of the Heart. AMSSM Exchange Lecture AOSSM 2013 Annual Meeting
Sports Cardiology: Matters of the Heart AMSSM Exchange Lecture AOSSM 2013 Annual Meeting Matthew Gammons, MD Vermont Orthopaedic Clinic Killington Medical Clinic Although sudden cardiac death is a relatively
More informationThe 2014 Mayo Approach to the Management of HCM and Non-Compaction
The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-1 Let
More informationUsefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity
Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity G.D.Aquaro, MD Fondazione G.Monasterio Regione Toscana/CNR Pisa, Italy
More informationRest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome
Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,
More informationAnaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)
Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Dr. Siân Jaggar Consultant Anaesthetist Royal Brompton Hospital London UK Congenital Cardiac Services
More informationΜΥΟΚΑΡΔΙΟΠΑΘΕΙΕΣ. Ανεξήγητη βραδυκαρδία µε ή χωρίς διαταραχές κολποκοιλιακής αγωγής: τι µπορεί να κρύβει? ΕΦΗ Ι. ΠΡΑΠΠΑ Καρδιολόγος
ΜΥΟΚΑΡΔΙΟΠΑΘΕΙΕΣ Ανεξήγητη βραδυκαρδία µε ή χωρίς διαταραχές κολποκοιλιακής αγωγής: τι µπορεί να κρύβει? ΕΦΗ Ι. ΠΡΑΠΠΑ Καρδιολόγος Β Καρδιολογική Κλινική, ΠΓΝΑ «Ο ΕΥΑΓΓΕΛΙΣΜΟΣ» CONFLICT of INTEREST : none
More informationSPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM
SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM Rio De Janeiro 2016 Sport and Exercise Cardiology Symposium SBC/SOCERJ ACC Sharlene M. Day, MD Associate Professor, Cardiovascular Medicine Director,
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationThe Management of HOCM: What are the Surgical Options
The Management of HOCM: What are the Surgical Options Konstadinos A Plestis, MD System Chief of Cardiac Thoracic and Vascular Surgery Main Line Health Care System Professor Sidney Kimmel Medical College
More informationCardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement
Cardiomyopathy Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement Nebraska Home Office Life Underwriters Association March 20, 2018 1 Cardiomyopathy A myocardial disorder in which
More informationHypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy A Presentation for the MUD meeting January, 2018 Reviewed by Bill Rooney MD VP/Medical Director 1 https://commons.wikimedia.org/wiki/file:blausen_0166_cardiomyopathy_hypertrophic.p
More informationIndex. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AEDs. See Automated external defibrillators (AEDs) AF. See Atrial fibrillation (AF) Age as factor in SD in marathon runners, 45 Antiarrhythmic
More informationHereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases
Hereditary Cardiovascular Conditions genetic testing for undiagnosed diseases What is Hypertrophic Cardiomyopathy (HCM)? normal heart heart with hcm Extra or thick heart muscle Typically in the left ventricle
More informationESC Guidelines on Hypertrophic Cardiomyopathy
2014 version ES Guidelines on Hypertrophic ardiomyopathy Pr Michel KOMAJDA Dept of ardiology HU PTE SALPETRERE University Pierre et Marie urie PARS FRANE European Heart Journal (2014):doi:10.1093/eurheartj/ehu284
More informationPre-participation screening is warranted: Pro
Controversies on marathon and beyond Pre-participation screening is warranted: Pro DOMENICO CORRADO, MD, PhD Department of Cardiac, Thoracic and Vascular Sciences University of Padova, Italy domenico.corrado@unipd.it
More informationthe Young Athlete David B. Gremmels, MD Pediatric Cardiologist Children s Hospitals and Clinics of MN
Cardiovascular Risk Assessment in the Young Athlete David B. Gremmels, MD Pediatric Cardiologist Children s Heart Clinic Children s Hospitals and Clinics of MN No disclosure or financial relationships
More informationJonathan Kim MD, FACC
Jonathan Kim MD, FACC Assistant Professor, Division of Cardiology, Emory University Adjunct Assistant Professor, School of Applied Physiology, Georgia Tech Team Cardiologist, Sports Medicine, Emory University
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationΠρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια:
Πρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια: Νεώτερα δεδομένα στη διαστρωμάτωση κινδύνου Εμμ. Μ. Κανουπάκης MD, PhD, FESC Πανεπιστημιακό Νοσοκομείο Ηρακλείου NIDCM Presence of LV dilatation
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationWhat You Should Know About Subcutaneous and Transvenous ICD
What You Should Know About Subcutaneous and Transvenous ICD N. A. Mark Estes III MD Professor of Medicine Tufts University School of Medicine Director, New England Cardiac Arrhythmia Center Tufts Medical
More informationSCD incidence in HCM
Great Debate Risk Stratification Strategies for Reliable Identification of High Risk Patients 2014 ESC Guidelines SCD incidence in HCM Ra8onale for a new approach How to iden8fy the minority of Pts at
More informationTreatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD
Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)
More informationEndurance sports and sudden cardiac death
Symposium: Endurance training and ventricular arrhythmias Endurance sports and sudden cardiac death DOMENICO CORRADO, MD, PhD Department of Cardiac, Thoracic and Vascular Sciences University of Padova,
More informationHCM in THE YOUNG Andre Keren MD Hadassah-Hebrew University Hospital, Jersualem, Israel
HCM in THE YOUNG Andre Keren MD Hadassah-Hebrew University Hospital, Jersualem, Israel Tel Aviv 5.6.09 Hypertrophic Cardiomyopathy Prevalence: Author n Method % Savage 1983 3000 M mode 0.3 Hada 1987 12841
More informationInterpretation and Consequences of Repolarisation Changes in Athletes
Interpretation and Consequences of Repolarisation Changes in Athletes Professor Sanjay Sharma E-mail sasharma@sgul.ac.uk @SSharmacardio Disclosures: None Athlete s ECG Vagotonia Sinus bradycardia Sinus
More informationHOCM: Alcohol ablation or LVOT Surgery: When and what?
HOCM: Alcohol ablation or LVOT Surgery: When and what? Paul R Vogt/ Pascal A. Berdat Cardiovascular Center Zurich Clinic Im Park Zurich SKG/SGHC Annual Meeting, Zurich, 10.-12.6.15 ASA/Myectomy: Common
More informationGenotype Positive/ Phenotype Negative: Is It a Disease?
Genotype Positive/ Phenotype Negative: Is It a Disease? Michelle Michels MD, PhD Center of Inherited Cardiovascular Diseases Erasmus MC, Rotterdam, the Netherlands No disclosures What is phenotype negative
More informationPVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.
PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?
More informationSudden Cardiac Arrest in Athletes Capital City Sports Summit June 7, 2012
Sudden Cardiac Arrest in Athletes Capital City Sports Summit June 7, 2012 John Katopodis, MD, FACC Southern Medical Group Cardiology Tallahassee, Florida Scope of the Problem Relating to Screening and
More informationCardiac MRI: Cardiomyopathy
Cardiac MRI: Cardiomyopathy Laura E. Heyneman, MD I do not have any relevant financial relationships with any commercial interests Cardiac MRI: Cardiomyopathy Laura E. Heyneman, MD Duke University Medical
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationImplantable Cardioverter Defibrillator (ICD)
Medical Coverage Policy Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 0181 Implantable Cardioverter Defibrillator (ICD) Table of Contents Related Coverage Resources
More informationThe Athlete s Heart. Role of Echo. Neil J. Weissman, MD MedStar Health Research Institute & Professor of Medicine Georgetown University
The Athlete s Heart Role of Echo Neil J. Weissman, MD MedStar Health Research Institute & Professor of Medicine Georgetown University Washington, D.C. Disclosures Grant support (to institution) for Core
More informationWhat s New in Cardiac MRI
What s New in Cardiac MRI Katie M. Hawthorne, MD Director, Cardiac MRI Main Line Health Philadelphia Cardiovascular Summit November 18, 2017 Cardiac MRI: Disclosure 2 Disclosures No financial disclosures
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More information9/17/2010. Phidippides. Phidippides. Sudden Death in the Young Athlete. What is the extent of the problem? Can we prevent it?
Phidippides Phidippides Sudden Death in the Young Athlete What is the extent of the problem? Can we prevent it? 1 Number of cardiovascular (CV), trauma-related, and other sudden death events in 1866 young
More informationInherited Arrhythmia Syndromes
Inherited Arrhythmia Syndromes When to perform Genetic testing? Arthur AM Wilde February 4, 2017 Which pts should undergo genetic testing? SCD victims with a likely diagnosis Pts diagnosed with an inherited
More informationHEART CONDITIONS IN SPORT
HEART CONDITIONS IN SPORT Dr. Anita Green CHD Risk Factors Smoking Hyperlipidaemia Hypertension Obesity Physical Inactivity Diabetes Risks are cumulative (multiplicative) Lifestyles predispose to RF One
More informationHypertrophic Cardiomyopathy
019-CardioCase:019-CardioCase 4/16/07 1:39 PM Page 19 Hypertrophic Cardiomyopathy Abdullah Alshehri, MD; and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Presley s check-up Presley, 37, discovered
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationSupplementary Online Content
Supplementary Online Content Tseng ZH, Hayward RM, Clark NM, et al. Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med. Published online June 22, 2015. doi:10.1001/jamainternmed.2015.2641.
More informationImaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD
Imaging in Heart Failure: A Multimodality Approach Thomas Ryan, MD Heart Failure HFrEF HFpEF EF50% Lifetime risk 20% Prevalence 6M Americans Societal costs - $30B 50% 5-year survival 1 Systolic
More informationAthletes with cardiac disease; dead and buried or chance for resurrection?
Athletes with cardiac disease; dead and buried or chance for resurrection? EuroPRevent 2011 Geneva F. Carré University Rennes 1-Pontchaillou Hospital Inserm U642, Rennes - F-35000 Risk of physical activity
More informationRole of CMR in heart failure and cardiomyopathy
Role of CMR in heart failure and cardiomyopathy Hajime Sakuma Department of Radiology, Mie University Late gadolinium enhancement (LGE) LGE MRI can demonstrate site of necrosis, fibrosis or deposition
More informationSurgical Myectomy for HOCM
Surgical Myectomy for HOCM Volkmar Falk Deutsches Herzzentrum Berlin Different Pathology of HOCM Impact on surgical strategy Said SM Expert Rev Cardiovasc Ther 2013 Different Pathology of HOCM Impact on
More informationAblative Therapy for Ventricular Tachycardia
Ablative Therapy for Ventricular Tachycardia Nitish Badhwar, MD, FACC, FHRS 2 nd Annual UC Davis Heart and Vascular Center Cardiovascular Nurse / Technologist Symposium May 5, 2012 Disclosures Research
More informationHypertrophic Cardiomyopathy. Sean Sliman PGY4 2/7/2017
Hypertrophic Cardiomyopathy Sean Sliman PGY4 2/7/2017 Goals Sprinkling HCM Knowledge Diagnosis Treatment Screening Board relevant Definition Hypertrophic cardiomyopathy (HCM) is LV hypertrophy associated
More informationCase based learning: CMR in Heart Failure
Case based learning: CMR in Heart Failure Milind Y Desai, MD FACC FAHA FESC Associate Professor of Medicine Heart and Vascular Institute, Cleveland Clinic Cleveland, OH Disclosures: none Use of Gadolinium
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More information